Can a zapping cap fight Alzheimer's? small trial hints at hope
NCT ID NCT03880240
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether a non-invasive brain stimulation method called tACS could reduce amyloid and tau proteins in people with mild to moderate Alzheimer's. Seventeen participants received daily sessions of tACS or a sham treatment for 2-4 weeks. The goal was to see if the stimulation could safely clear these proteins and improve memory.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- transcranial alternating current stimulation (tACS)
- What this could lead to
- If it works, this could point toward a non-drug way to slow Alzheimer's by clearing harmful brain proteins.
- What could go wrong
- This is a very small early-phase trial with only 17 people, so results may not apply broadly. The treatment is still experimental and may not show clear benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1/2
Runs two stages together: safety and dose first, then whether the treatment works.
- Participants
-
17 people
The number who actually took part.
- Started
-
Aug 2019
- Finished
-
Nov 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
45 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Clinical Diagnosis of early to moderate AD\* * Mini Mental State Examination (MMSE) ≥ 18 * Clinical Dementia Rating (CDR) ≥ 0.5 * Demonstration or history of memory impairments. * Confirmation of diagnosis will be made by the study MD based on a holistic consideration of the participant's cognitive evaluation and history. * Amyloid positive PET imaging * At least 45 years old * On a stable dose of medications for memory loss including cholinesterase inhibitors (e.g. donepezil, rivastigmine or memantine) as defined as 6 consecutive weeks of treatment at an unchanging dose * Minimum of completed 8th grade education * No history of intellectual disability Exclusion Criteria: * Current history of poorly controlled migraines including chronic medication for migraine prevention * Current or past history of any neurological disorder other than dementia, such as epilepsy, stroke (cortical stroke), progressive neurologic disease (e.g. multiple sclerosis) or intracranial brain lesions; and history of previous neurosurgery or head trauma that resulted in residual neurologic impairment. * Non-cortical disease such as confluence white matter changes (including lacunar infarcts \< 1cm) and asymptomatic, subacute, cerebellar infarcts may be included upon review of a medically responsible neurologist. * Past or current history of major depression, bipolar disorder or psychotic disorders, or any other major psychiatric condition. * Contraindication for undergoing MRI or receiving TMS or tACS, * \>50 mSv of radiation exposure for research within the past year (PET imaging exclusion) * History of fainting spells of unknown or undetermined etiology that might constitute seizures. * History of seizures, diagnosis of epilepsy, history of abnormal (epileptiform) EEG or immediate (1st degree relative) family history of epilepsy; with the exception of a single seizure of benign etiology (e.g. febrile seizure) in the judgment of the investigator. * Chronic (particularly) uncontrolled medical conditions that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.). * Metal implants (excluding dental fillings) or devices such as pacemaker, medication pump, nerve stimulator, TENS unit, ventriculo-peritoneal shunt, cochlear implant, unless cleared by the study MD. * Substance abuse or dependence within the past six months. * Medications will be reviewed by the responsible MD and a decision about inclusion will be made based on the following: The patient's past medical history, drug dose, history of recent medication changes or duration of treatment, and combination of CNS active drugs. * All female participants that are pre-menopausal will be required to have a pregnancy test; any participant who is pregnant or breastfeeding will not be enrolled in the study. * Subjects who, in the investigator's opinion, might not be suitable for the study * A hair style or head dress that prevents electrode contact with the scalp or would interfere with the stimulation (for example: thick braids, hair weave, afro, wig)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut bacteria may hold clues to dozens of diseases
- Can a personalized home program slow memory decline?
- Can a massive data registry crack the code of Parkinson's and related brain diseases?
- Can a gentle electric current calm the mind in Alzheimer's?
- Alzheimer's vaccine aims to clear amyloid before memory fades
- Blood, eye, and brain scans team up to spot Alzheimer's earlier